BFRG News & Events

BullFrog AI announced a commercial agreement with a global pharmaceutical company to apply the company's proprietary bfLEAP platform to identify and prioritize novel drug targets in major depressive disorder, accelerating the customer's drug discovery and clinical development program for this indication. The agreement also provides exclusive access to a target candidate

BullFrog AI Holdings announces the coming launch of a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design. Key capabilities include: Compares drug programs, indications, and trial designs without forcing arbitrary numerical scores; Tests portfolio decisions against multiple explicit scenarios; Identifies options that perform well across strategic futures; Preserves portfolio diversity while surfacing clear leaders to balance concentration with risk mitigation

BullFrog AI Holdings publishes a white paper titled, "Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences," with a discussion on how BullFrog AI's bfPREP immediately recognizes reliable patterns to transform raw biomedical data into harmonized, clinically contextualized formats, providing reliable insights and trustworthy analytical assets to assist in drug development. "The rush to apply AI in biopharma drug development has resulted in many AI initiatives that fail, not due to the algorithm, but due to the resulting analysis that reflect data processing idiosyncrasies rather than biology," said CEO Vin Singh. "The white paper discusses how BullFrog makes messy biomedical data usable, with our experienced data team quick to recognize the typical state of the underlying data, which is often fragmented across sources and trapped in formats that resist automated processing. Our proprietary bfPREP addresses all this by harmonizing and standardizing raw data into clean, analysis-ready datasets so that teams can comfortably trust their inputs." The white paper outlines where modern AI pipelines break in life sciences and presents a practical harmonization framework built on three pillars: engineering clinically meaningful derived features, producing reliable categorical variables and harmonized schemas, and transforming unstructured clinical documents into analysis-ready tables.

BullFrog AI highlights the presentation of data derived from the use of the Company's proprietary platform bfLEAP with pancreatic cancer trial data to identify an almost three times increase in mean survival from the control to treatment arms. The data will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium on Jan. 9 at poster session B. "The glufosfamide case study in pancreatic cancer successfully showcased the utility of our platform to provide drug developers with an end-to-end analytical tool engineered to resolve multimodal biological complexity at scale," said BullFrog AI Founder and CEO Vin Singh. "Too much time and capital are wasted in drug development traveling down incorrect pathways, ultimately leaving patients without effective treatments. The power of bfLEAP and bfPREP is their ability to give drug developers a clear path forward based on previous data and indicators to focus on key benchmarks, limiting the amount of wasteful spending on less-than-ideal targets."